Seragon Pharmaceuticals Inc. July 2 announced a definitive agreement under which Genentech will acquire Seragon for $725 million in cash and $1 billion in contingent development milestone payments.
Seragon, founded in August 2013, is an independent, venture-backed biotech company based in San Diego that was spun out of Aragon Pharmaceuticals following its acquisition by Johnson & Johnson11 PLIR 788, 6/21/13. Seragon develops small-molecule drugs for the treatment of estrogen receptor-dependent breast cancer.
The acquisition includes Seragon’s selective estrogen receptor degraders (SERDs) program, including its most advanced compound, ARN-810, a next-generation SERD that is being evaluated in a phase ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.